哈马林对背部条状神经元的毒性及其在震中的作用
Xiping Zhan1, Ly V Do2, Li Zou2
1Department of Physiology and Biophysics, College of Medicine, Howard University, Washington, DC 20059, USA; Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Neurotoxicology
|October 14, 2023
概括
哈马林是体内的一种化合物,可以引起震. 这项研究表明,harmaline会影响条状神经元和多巴胺D2信号传递,这表明了基本震的新机制.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 哈马林是一种β-卡博林,存在于人体组织中,与基本震 (ET) 和帕金森病有关.
- 哈马林诱导震和神经退行,作为ET的动物模型,但其精确的机制仍然不清楚.
- 现有的假设集中在下层橄-小脑通路和CaV3.1 T型通道上,尽管有证据表明其他机制也参与其中.
研究的目的:
- 为了研究底层的harmaline诱导震的神经回路和分子目标.
- 探索背上条纹体和多巴胺D2信号在哈马林神经毒性作用中的作用.
主要方法:
- 在体外切片成像和补丁电生理学中等棘状条状神经元 (MSN).
- 评估哈马林对细胞内水平和神经元活动的影响.
- 使用硫化物进行药理学操纵,以评估其调节作用.
- 在小鼠体内实验中,评估哈马林诱导的震及其通过硫化物减弱的情况.
主要成果:
- 哈马林降低了细胞内,并抑制了MSN的尖端活动.
- 哈马林显著减弱了MSN中的自发刺激后突触电流 (sEPSCs).
- 硫皮化物部分逆转了哈马林对MSN的影响,并在小鼠中显著减弱了哈马林诱导的震.
结论:
- 背上条纹体被认为是harmaline有毒作用的部位,有助于产生震.
- 建议多巴胺D2受体信号参与harmaline诱导的震和潜在的基本震的机制.
相关概念视频
01:24Parkinson's Disease: Treatment
283
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
283
01:23Drugs Acting on Autonomic Ganglia: Stimulants
1.4K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
1.4K
01:29Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.1K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.1K
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
698
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
698
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
354
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
354